Combining CDP-choline and galantamine: Effects of a selective α7 nicotinic acetylcholine receptor agonist strategy on P50 sensory gating of speech sounds in healthy volunteers

Abstract

Background:

Schizophrenia (SCZ) patients and relatives have deficits in early cortical sensory gating (SG) typically measured by suppression of electroencephalography-derived P50 event-related potentials (ERPs) in a conditioning-testing (S₁–S₂) paradigm. Associated with alpha 7 nicotinic acetylcholine receptor (α7 nAChR) dysfunction and shown to be improved with nicotine and α7 nAChR agonists, SG has recently been shown to be improved in low P50 suppressing SCZ patients following acute CDP-choline treatment.

Aims:

This pilot study in healthy humans assessed the SG effects of an α7 nAChR strategy combining CDP-choline with galantamine, a positive allosteric modulator (PAM) of nAChRs, aimed at increasing and prolonging nicotinic receptor activity.

Methods:

The combined effect of CDP-choline (500 mg) and galantamine (16 mg) on speech P50 gating indices rP50 (S₂/S₁) and dP50 (S₁–S₂) was examined in 30 healthy participants stratified into low and high baseline P50 suppressors in a randomized, double-blind, placebo-controlled and counterbalanced design.

Results:

In low suppressors, CDP-choline/galantamine (vs. placebo) improved rP50 and dP50 gating, and reduced S₂P50 amplitudes. No P50 gating effects were observed in high suppressors; however, CDP-choline/galantamine (vs. placebo) increased their S₂P50 amplitudes.

Conclusion:

Findings from this pilot study with CDP-choline/galantamine in a healthy, SCZ-like surrogate deficient gating sample are consistent with the association of α7 nAChR mechanisms in SG impairment in SCZ and support further research trials with CDP-choline and galantamine targeting sensory processes.

Keywords

α7 nAChR CDP-choline ERP galantamine P50 PAM P50 suppression schizophrenia sensory gating

Get full access to this article

View all access options for this article.

References

Adibhatla

Hatcher

Dempsey

(2001) Effects of citicoline on phospholipid and glutathione levels in transient cerebral ischemia. Stroke 32: 2376–2381.

Adler

Hoffer

Griffith

et al . (1992) Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol Psychiatry 32: 607–616.

Adler

Olincy

Cawthra

et al . (2004) Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients. Am J Psychiatry 161: 1822–1828.

Adler

Cawthra

Donovan

et al . (2005) Improved P50 auditory gating with ondansetron in medicated schizophrenia patients. Am J Psychiatry 162: 386–388.

Adler

Olincy

Waldo

et al . (1998) Schizophrenia, sensory gating, and nicotinic receptors. Schizophr Bull 24: 189–202.

Agut

Ortiz

Wurtman

(2000) Cytidine (5’)diphosphocholine modulates dopamine K(+)-evoked release in striatum measured by microdialysis. Ann N Y Acad Sci 920: 332–335.

Aidelbaum

Labelle

Baddeley

et al . (2018) Assessing the acute effects of CDP-choline on sensory gating in schizophrenia: A pilot study. J Psychopharmacol 32: 541–551.

Albuquerque

Pereira

EFR

Braga

MFM

et al . (1998) Contribution of nicotinic receptors to the function of synapses in the central nervous system: The action of choline as a selective agonist of alpha 7 receptors. J Physiol Paris 92: 309–316.

Azzopardi

Typlt

Jenkins

et al . (2013) Sensorimotor gating and spatial learning in alpha 7-nicotinic receptor knockout mice. Genes Brain Behav 12: 414–423.

10.

Bertrand

Terry

Jr. (2018) The wonderland of neuronal nicotinic acetylcholine receptors. Biochem Pharmacol 151: 214–225.

11.

Boggs

Carlson

Cortes-Briones

et al . (2014) Going up in smoke? A review of nAChRs-based treatment strategies for improving cognition in schizophrenia. Curr Pharm Des 20: 5077–5092.

12.

Boggs

Surti

Esterlis

et al . (2018) Minimal effects of prolonged smoking abstinence or resumption on cognitive performance challenge the ‘self-medication’ hypothesis in schizophrenia. Schizophr Res 194: 62–69.

13.

Boutros

Belger

Campbell

et al . (1999) Comparison of four components of sensory gating in schizophrenia and normal subjects: A preliminary report. Psychiatry Res 88: 119–130.

14.

Boutros

Gjini

Eickhoff

et al . (2013) Mapping repetition suppression of the P50 evoked response to the human cerebral cortex. Clin Neurophysiol 124: 675–685.

15.

Boutros

Korzyukov

Jansen

et al . (2004) Sensory gating deficits during the mid-latency phase of information processing in medicated schizophrenia patients. Psychiatry Res 126: 203–215.

16.

Braff

(1990) Sensorimotor gating and schizophrenia. Arch Gen Psychiatry 47: 181–188.

17.

Braff

(2011) Gating in schizophrenia: From genes to cognition (to real world function?). Biol Psychiatry 69: 395–396.

18.

Braff

Freedman

(2002) Endophenotypes in studies of the genetics of schizophrenia. In: Neuropsychopharmacology: The Fifth Generation of Progress, Philadelphia, PA: Lippincott, Williams & Wilkins, pp. 703–716.

19.

Braff

Freedman

Schork

et al . (2007) Deconstructing schizophrenia: An overview of the use of endophenotypes in order to understand a complex disorder. Schizophr Bull 33: 21–32.

20.

Bramon

Rabe-Hesketh

Sham

et al . (2004) Meta-analysis of the P300 and P50 waveforms in schizophrenia. Schizophr Res 70: 315–329.

21.

Brockhaus-Dumke

Schultze-Lutter

Mueller

et al . (2008) Sensory gating in schizophrenia: P50 and N100 gating in antipsychotic-free subjects at risk, first-episode, and chronic patients. Biol Psychiatry 64: 376–384.

22.

Brown

Kuperberg

(2015) A hierarchical generative framework of language processing: Linking language perception, interpretation, and production abnormalities in schizophrenia. Front Hum Neurosci 9: 643.

23.

Buchanan

Conley

Dickinson

et al . (2008) Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry 165: 82–89.

24.

Cadenhead

Light

Geyer

et al . (2000) Sensory gating deficits assessed by the P50 event-related potential in subjects with schizotypal personality disorder. Am J Psychiatry 157: 55–59.

25.

Castner

Smagin

Piser

et al . (2011) Immediate and sustained improvements in working memory after selective stimulation of α7 nicotinic acetylcholine receptors. Biol Psychiatry 69: 12–18.

26.

Cather

Pachas

Cieslak

et al . (2017) Achieving smoking cessation in individuals with schizophrenia: Special considerations. CNS Drugs 31: 471–481.

27.

Clementz

(1998) Psychophysiological measures of (dis)inhibition as liability indicators for schizophrenia. Psychophysiology 35: 648–668.

28.

Clementz

Geyer

Braff

(1998) Poor P50 suppression among schizophrenia patients and their first-degree biological relatives. Am J Psychiatry 155: 1691–1694.

29.

Court

Spurden

Lloyd

et al . (1999) Neuronal nicotinic receptors in dementia with lewy bodies and schizophrenia: Alpha-bungarotoxin and nicotine binding in the thalamus. J Neurochem 73: 1590–1597.

30.

Csomor

Preller

Geyer

et al . (2014) Influence of aripiprazole, risperidone, and amisulpride on sensory and sensorimotor gating in healthy ‘low and high gating’ humans and relation to psychometry. Neuropsychopharmacology 39: 2485–2496.

31.

Csomor

Stadler

Feldon

et al . (2008) Haloperidol differentially modulates prepulse inhibition and P50 suppression in healthy humans stratified for low and high gating levels. Neuropsychopharmacology 33: 497–512.

32.

Cullum

Harris

Waldo

et al . (1993) Neurophysiological and neuropsychological evidence for attentional dysfunction in schizophrenia. Schizophr Res 10: 131–141.

33.

Dalecki

Johnstone

Croft

(2015) Clarifying the functional process represented by P50 suppression. Genes Brain Behav 96: 149–154.

34.

Dani

Bertrand

(2007) Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxicol 47: 699–729.

35.

de la Salle

Smith

Choueiry

et al . (2013) Effects of COMT genotype on sensory gating and its modulation by nicotine: Differences in low and high P50 suppressors. Neuroscience 241: 147–156.

36.

de Leede-Smith

Barkus

(2013) A comprehensive review of auditory verbal hallucinations: Lifetime prevalence, correlates and mechanisms in healthy and clinical individuals. Front Hum Neurosci 7: 367.

37.

Deutsch

Rosse

Schwartz

et al . (2008a) Effects of CDP-choline and the combination of CDP-choline and galantamine differ in an animal model of schizophrenia: Development of a selective alpha7 nicotinic acetylcholine receptor agonist strategy. Eur Neuropsychopharmacol 18: 147–151.

38.

Deutsch

Schwartz

Schooler

et al . (2008b) First administration of cytidine diphosphocholine and galantamine in schizophrenia: A sustained alpha7 nicotinic agonist strategy. Clin Neuropharmacol 31: 34–39.

39.

Deutsch

Schwartz

Schooler

et al . (2013) Targeting alpha-7 nicotinic neurotransmission in schizophrenia: A novel agonist strategy. Schizophr Res 148: 138–144.

40.

Dinklo

Shaban

Thuring

et al . (2011) Characterization of 2-[[4-fluoro-3-(trifluoromethyl)phenyl]amino]-4-(4-pyridinyl)-5-thiazolemethanol (JNJ-1930942), a novel positive allosteric modulator of the α7 nicotinic acetylcholine receptor. J Pharmacol Exp Ther 336: 560–574.

41.

Erwin

Turetsky

Moberg

et al . (1998) P50 abnormalities in schizophrenia: Relationship to clinical and neuropsychological indices of attention. Schizophr Res 33: 157–167.

42.

Faugere

Micoulaud-Franchi

Boyer

et al . (2016) Does sensory gating have a protective effect against hallucinatory behavior in schizophrenia? Clin Neurophysiol 127: 1746–1748.

43.

Frazier

Rollins

Breese

et al . (1998) Acetylcholine activates an alpha-bungarotoxin-sensitive nicotinic current in rat hippocampal interneurons, but not pyramidal cells. J Neurosci 18: 1187-1195.

44.

Freedman

Hall

Adler

et al . (1995) Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 38: 22–33.

45.

Freedman

Waldo

Bickford-Wimer

et al . (1991) Elementary neuronal dysfunctions in schizophrenia. Schizophr Res 4: 233–243.

46.

Fuerst

Gallinat

Boutros

(2007) Range of sensory gating values and test-retest reliability in normal subjects. Psychophysiology 44: 620–626.

47.

Gareri

Castagna

Cotroneo

et al . (2017) The citicholinage study: Citicoline plus cholinesterase inhibitors in aged patients affected with Alzheimer’s disease study. J Alzheimers Dis 56: 557–565.

48.

Geyer

(2006) Are cross-species measures of sensorimotor gating useful for the discovery of procognitive cotreatments for schizophrenia? Dialogues Clin Neurosci 8: 9–16.

49.

Giakoumaki

(2012) Cognitive and prepulse inhibition deficits in psychometrically high schizotypal subjects in the general population: Relevance to schizophrenia research. J Int Neuropsychol Soc 18: 643–656.

50.

Grasing

(2016) A threshold model for opposing actions of acetylcholine on reward behavior: Molecular mechanisms and implications for treatment of substance abuse disorders. Behav Brain Res 312: 148–162.

51.

Gratton

Coles

MGH

Donchin

(1983) A new method for off-line removal of ocular artifact. Electroencephalogr Clin Neurophysiol 55: 468–484.

52.

Guan

Zhang

Ravid

et al . (2000) Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer’s disease. J Neurochem 74: 237–243.

53.

Hahn

Shoaib

Stolerman

(2002) Nicotine-induced enhancement of attention in the five-choice serial reaction time task: The influence of task demands. Psychopharmacology (Berl) 162: 129–137.

54.

Hashimoto

(2015) Targeting of α7 nicotinic acetylcholine receptors in the treatment of schizophrenia and the use of auditory sensory gating as a translational biomarker. Curr Pharm Des 21: 3797–3806.

55.

Hirano

Maekawa

et al . (2010) Auditory gating deficit to human voices in schizophrenia: A MEG study. Schizophr Res 117: 61–67.

56.

Hohnadel

Bouchard

Terry

(2007) Galantamine and donepezil attenuate pharmacologically induced deficits in prepulse inhibition in rats. Neuropharmacology 52: 542–551.

57.

Holstein

Csomor

Geyer

et al . (2011) The effects of sertindole on sensory gating, sensorimotor gating, and cognition in healthy volunteers. J Psychopharmacol 25: 1600–1613.

58.

Hyde

Choueiry

Smith

et al . (2016) Cholinergic modulation of auditory P3 event-related potentials as indexed by CHRNA4 and CHRNA7 genotype variation in healthy volunteers. Neurosci Lett 623: 36–41.

59.

Jann

Shirley

Small

(2002) Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 41: 719–739.

60.

Javanbakht

(2006) Sensory gating deficits, pattern completion, and disturbed fronto-limbic balance, a model for description of hallucinations and delusions in schizophrenia. Med Hypotheses 67: 1173–1184.

61.

Javitt

Freedman

(2015) Sensory processing dysfunction in the personal experience and neuronal machinery of schizophrenia. Am J Psychiatry 172: 17–31.

62.

Jones

Hills

Dick

et al . (2016) Cognitive mechanisms associated with auditory sensory gating. Brain Cogn 102: 33–45.

63.

Knott

Choueiry

Dort

et al . (2014) Baseline-dependent modulating effects of nicotine on voluntary and involuntary attention measured with brain event-related P3 potentials. Pharmacol Biochem Behav 122: 107–117.

64.

Knott

Fisher

Millar

(2010) Differential effects of nicotine on P50 amplitude, its gating, and their neural sources in low and high suppressors. Neuroscience 170: 816–826.

65.

Knott

Impey

Choueiry

et al . (2015a) An acute dose, randomized trial of the effects of CDP-Choline on Mismatch Negativity (MMN) in healthy volunteers stratified by deviance detection level. Neuropsychiatr Electrophysiol 1: 1.

66.

Knott

de la Salle

Smith

et al . (2015b) Effects of acute CDP-choline treatment on resting state brain oscillations in healthy volunteers. Neurosci Lett 591: 121–125.

67.

Knott

de la Salle

Choueiry

et al . (2015c) Neurocognitive effects of acute choline supplementation in low, medium and high performer healthy volunteers. Pharmacol Biochem Behav 131: 119–129.

68.

Knott

de la Salle

Smith

et al . (2013) Baseline dependency of nicotine’s sensory gating actions: Similarities and differences in low, medium and high P50 suppressors. J Psychopharmacol 27: 790–800.

69.

Knott

Smith

De La Salle

et al . (2014) CDP-choline: Effects of the procholine supplement on sensory gating and executive function in healthy volunteers stratified for low, medium and high P50 suppression. J Psychopharmacol 28: 1095–1108.

70.

Koukouli

Maskos

(2015) The multiple roles of the α7 nicotinic acetylcholine receptor in modulating glutamatergic systems in the normal and diseased nervous system. Biochem Pharmacol 97: 378–387.

71.

Kumari

Postma

(2005) Nicotine use in schizophrenia: The self medication hypotheses. Neurosci Biobehav Rev 25: 1021–1034.

72.

Leonard

Adams

Breese

et al . (1996) Nicotinic receptor function in schizophrenia. Schizophr Bull 22: 431–445.

73.

Leonard

Gault

Hopkins

et al . (2002) Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. Arch Gen Psychiatry 59: 1085–1096.

74.

Mackowick

Barr

Wing

et al . (2013) Neurocognitive endophenotypes in schizophrenia: Modulation by nicotinic receptor systems. Prog Neuropsychopharmacol Biol Psychiatry 52: 79–85.

75.

Maxwell

(1992) Family Interview for Genetic Studies (FIGS). Available at: https://www.nimhgenetics.org/interviews/figs/figs_train.pdf.

76.

Millar

Smith

Choueiry

et al . (2011) The moderating role of the dopamine transporter 1 gene on P50 sensory gating and its modulation by nicotine. Neuroscience 180: 148–156.

77.

Miller

Freedman

(1995) The activity of hippocampal interneurons and pyramidal cells during the response of the hippocampus to repeated auditory stimuli. Neuroscience 69: 371–381.

78.

Nagamoto

Adler

Waldo

et al . (1991) Gating of auditory response in schizophrenics and normal controls. Effects of recording site and stimulation interval on the P50 wave. Schizophr Res 4: 31–40.

79.

Nees

(2015) The nicotinic cholinergic system function in the human brain. Neuropharmacology 96(Pt B): 289–301.

80.

Olfson

Gerhard

Huang

et al . (2015) Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry 72: 1172–1181.

81.

Oranje

Aggernaes

Rasmussen

et al . (2013) P50 suppression and its neural generators in antipsychotic-naïve first-episode schizophrenia before and after 6 months of quetiapine treatment. Schizophr Bull 39: 472–480.

82.

Pabst

Braganza

Dannenberg

et al . (2016) Astrocyte intermediaries of septal cholinergic modulation in the hippocampus. Neuron 90: 853–865.

83.

Patterson

Hetrick

Boutros

et al . (2008) P50 sensory gating ratios in schizophrenics and controls: a review and data analysis. Psychiatry Res 158: 226–247.

84.

Potter

Summerfelt

Gold

et al . (2006) Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia. Schizophr Bull 32: 692–700.

85.

Prickaerts

Van Goethem

Chesworth

et al . (2012) EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors. Neuropharmacology 62: 1099–1110.

86.

Ross

Hunter

McCarthy

et al . (2013) Perinatal choline effects on neonatal pathophysiology related to later schizophrenia risk. Am J Psychiatry 170: 290–298.

87.

Scott

Goa

(2000) Galantamine: A review of its use in Alzheimer’s disease. Drugs 60: 1095–1122.

88.

Secades

(2011) Citicoline: Pharmacological and clinical review, 2010 update. Rev Neurol 52(Suppl 2): S1–S62.

89.

Shao

et al . (2014) Galanthamine, an acetylcholine inhibitor, prevents prepulse inhibition deficits induced by adolescent social isolation or MK-801 treatment. Brain Res 1589: 105–111.

90.

Smith

Edgar

Huang

et al . (2010) Cognitive abilities and 50- and 100-msec paired-click processes in schizophrenia. Am J Psychiatry 167: 1264–1275.

91.

Smith

Grant

Fisher

et al . (2013) Auditory verbal hallucinations in schizophrenia correlate with P50 gating. Clin Neurophysiol 124: 1329–1335.

92.

Smucny

Olincy

Eichman

et al . (2013) Early sensory processing deficits predict sensitivity to distraction in schizophrenia. Schizophr Res 147: 196–200.

93.

Smucny

Stevens

Olincy

et al . (2015) Translational utility of rodent hippocampal auditory gating in schizophrenia research: A review and evaluation. Transl Psychiatry 5: e587.

94.

Stevens

Choo

Stitzel

et al . (2014) Long-term improvements in sensory inhibition with gestational choline supplementation linked to α7 nicotinic receptors through studies in Chrna7 null mutation mice. Brain Res 1552: 26–33.

95.

Cai

Wang

et al . (2012) Various effects of antipsychotics on p50 sensory gating in Chinese schizophrenia patients: A meta-analysis. Psychiatr Danub 24: 44–50.

96.

Thoma

Meier

Houck

et al . (2017) Diminished auditory sensory gating during active auditory verbal hallucinations. Schizophr Res 188: 125–131.

97.

Turetsky

Calkins

Light

G a

et al . (2007) Neurophysiological endophenotypes of schizophrenia: The viability of selected candidate measures. Schizophr Bull 33: 69–94.

98.

Wallace

Bertrand

(2015) Neuronal alpha7 nicotinic receptors as a target for the treatment of schizophrenia. Int Rev Neurobiol 124: 79–111.

99.

Werkheiser

Sydserff

Hubbs

et al . (2011) Ultra-low exposure to alpha-7 nicotinic acetylcholine receptor partial agonists elicits an improvement in cognition that corresponds with an increase in alpha-7 receptor expression in rodents: Implications for low dose clinical efficacy. Neuroscience 186: 76–87.

100.

Williams

JBW

Gibbon

First

et al . (1992) The Structured Clinical Interview for DSM-III-R (SCID ): II. Multisite test-retest reliability. Arch Gen Psychiatry 49: 630–636.

101.

Winterer

Gallinat

Brinkmeyer

et al . (2013) Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: A proof-of-mechanism study. Neuropharmacology 64: 197–204.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.07 MB